{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.65","value":"22.04"},{"groupId":"OG001","spread":"5.51","value":"22.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"191"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.59","value":"-0.21"},{"groupId":"OG001","spread":"3.87","value":"-0.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"155"},{"groupId":"OG001","value":"158"}],"units":"Participants"}],"title":"CFB at Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.67","value":"-1.00"},{"groupId":"OG001","spread":"2.83","value":"3.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"CFB at Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.32","value":"-0.34"},{"groupId":"OG001","spread":"4.33","value":"-0.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"149"}],"units":"Participants"}],"title":"CFB at Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.21","value":"-0.65"},{"groupId":"OG001","spread":"3.60","value":"-0.88"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"145"}],"units":"Participants"}],"title":"CFB at End of Induction Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.83","value":"-0.02"},{"groupId":"OG001","spread":"5.37","value":"-0.57"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"title":"CFB at Follow-up Month 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.65","value":"0.27"},{"groupId":"OG001","spread":"5.02","value":"-0.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"125"}],"units":"Participants"}],"title":"CFB at Follow-up Month 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.46","value":"0.05"},{"groupId":"OG001","spread":"4.64","value":"-0.08"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"114"}],"units":"Participants"}],"title":"CFB at Follow-up Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.67","value":"-0.68"},{"groupId":"OG001","spread":"4.99","value":"-0.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"191"}],"units":"Participants"}],"title":"CFB at Follow-up Month 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.00","value":"0.56"},{"groupId":"OG001","spread":"5.14","value":"0.13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"94"}],"units":"Participants"}],"title":"CFB at Follow-up Month 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.89","value":"0.06"},{"groupId":"OG001","spread":"5.64","value":"-0.47"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"93"}],"units":"Participants"}],"title":"CFB at Follow-up Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.28","value":"0.56"},{"groupId":"OG001","spread":"4.16","value":"-0.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"89"}],"units":"Participants"}],"title":"CFB at Follow-up Month 14"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.79","value":"0.36"},{"groupId":"OG001","spread":"5.28","value":"-0.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"85"}],"units":"Participants"}],"title":"CFB at Follow-up Month 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.23","value":"0.44"},{"groupId":"OG001","spread":"5.35","value":"0.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"78"}],"units":"Participants"}],"title":"CFB at Follow-up Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.28","value":"-0.66"},{"groupId":"OG001","spread":"5.75","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"title":"CFB at Follow-up Month 20"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.12","value":"0.29"},{"groupId":"OG001","spread":"5.02","value":"-0.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"title":"CFB at Follow-up Month 22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.91","value":"-1.29"},{"groupId":"OG001","spread":"5.24","value":"-0.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"71"}],"units":"Participants"}],"title":"CFB at Follow-up Month 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.91","value":"-0.19"},{"groupId":"OG001","spread":"5.56","value":"-0.52"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"109"}],"units":"Participants"}],"title":"CFB at Final Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.49","value":"-0.35"},{"groupId":"OG001","spread":"4.92","value":"-0.16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"title":"CFB at Extension Follow-up Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.92","value":"-0.15"},{"groupId":"OG001","spread":"5.26","value":"0.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"49"}],"units":"Participants"}],"title":"CFB at Extension Follow-up Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.18","value":"-0.41"},{"groupId":"OG001","spread":"5.02","value":"0.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"title":"CFB at Extension Follow-up Month 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"191"}],"units":"Participants"}],"description":"The FACT-Lym measures 5 sub-scales which includes 42 items; responses to each item range from 0, \"Not at all\" to 4, \"Very much\". Total score ranges from 0-168. Social/family Well-being sub-scale includes 7 items measured on 0-4 point scale. The total score for social/family well-being sub-scale is sum of each 7 items (range: 0-28). Higher scores indicate a better PRO/QoL. In timeframe, follow-up months represents months after end of induction (e.g. Follow-up Month 2 is 2 months after end of induction) and extension follow-up months represents months after end of 2 years normal follow-up (e.g. extension follow-up Month 6 is 6 months after end of normal 2 year follow-up).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Bendamustine 120 mg/m\\^2 IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.","id":"OG000","title":"Bendamustine Alone"},{"description":"Induction phase: Participants received Bendamustine 90 mg/m\\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with CR, PR or SD then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).","id":"OG001","title":"Obinutuzumab + Bendamustine"}],"paramType":"MEAN","populationDescription":"ITT population. Here, number of participants analyzed signified those participants who were evaluable for this outcome and \"n\" signified those participants who were evaluable for a specified time point.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of Cycles 3, 4, 5, End of induction treatment (up to Month 6); Follow-up Months 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, Final Follow-up (up to 2 years after end of induction); Extension follow-up Months 6, 18 and 24","title":"CFB in FACT-Lym-Social/Family Well-being Sub-scale Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}